寺岡 雄吏YUJI TERAOKA
Last Updated :2023/02/02
- 所属・職名
- 病院(医) 助教
- メールアドレス
- teraoka22
hiroshima-u.ac.jp
- 自己紹介
- 消化器・代謝内科学にて主に肝臓の基礎研究を行っています。また、実習活動等を通して、医学生への指導を行っています。よろしくお願いいたします。
基本情報
学歴
- 広島大学, 大学院医歯薬保健学研究科, 日本, 2016年04月, 2019年09月
学位
研究分野
- 医歯薬学 / 内科系臨床医学 / 消化器内科学
- 医歯薬学 / 基礎医学 / ウイルス学
研究キーワード
所属学会
- 日本内視鏡学会 内視鏡専門医
- 日本肝臓学会 肝臓専門医
- 日本消化器病学会 消化器病専門医
- 日本内科学会 総合内科専門医
教育活動
授業担当
- 2022年, 学部専門, 通年, 器官・システム病態制御学I
- 2022年, 学部専門, 集中, 臨床実習入門プログラム
- 2022年, 学部専門, 集中, 臨床実習I
- 2022年, 学部専門, 集中, 臨床実習II
研究活動
学術論文(★は代表的な論文)
- Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84巻, 3号, pp. 391-399, 202203
- Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, Biochemical and Biophysical Research, 500巻, pp. 152-157, 2018
- Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, Journal of General Virology, 99巻, pp. 1058-1065, 2018
- Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, Hepatology Research, 48巻, pp. 193-204
- 胆管細胞癌における造影超音波検査所見の検討, 肝臓, 58巻, pp. 654-663
- Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 2号, pp. 267-270, 202004
- Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
- Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection, JOURNAL OF CLINICAL INVESTIGATION, 130巻, 6号, pp. 3205-3220, 20200601
- Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
- Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion, Nat Microbiol
- Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, Hepatol Commun . 2019 Jan 22;3(3):348-355
- Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, Hepatol Res . 2018 Jan;48(1):51-58.
- Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, J Gen Virol . 2019 Jul;100(7):1123-1131.
- Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, J Med Virol . 2020 Feb;92(2):210-218.
- Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, J Gastroenterol . 2019 Mar;54(3):291-296.
- Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection, J Clin Invest . 2020 Jun 1;130(6):3205-3220.
- Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLoS One . 2018 Apr 3;13(4):e0195028.
- Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, Hepatol Res . 2018 Dec;48(13):1118-1130.
- Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, J Gastroenterol . 2018 Jan;53(1):161-162.
- The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, J Med Virol . 2019 Apr;91(4):650-658.
- Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, J Gastroenterol . 2017 Dec;52(12):1252-1257.
- Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, Hepatol Res . 2018 Mar;48(4):264-274.
- The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLoS One . 2017 Aug 10;12(8):e0182710.
- Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, Oncology . 2017;92(6):335-346.
- Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, J Med Virol . 2017 Nov;89(11):1963-1972.
- Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction, J Med Virol . 2017 Apr;89(4):665-671.
- Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, Hepatol Res . 2020 Aug 6.
- Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, Hepatol Res . 2020 Sep 11.
- Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion, NATURE MICROBIOLOGY, 5巻, 12号, pp. 1532-+, 202012
- Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1234-1243, 202011
- Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28巻, 2号, pp. 400-409, 202102
- Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60巻, 6号, pp. 829-837, 2021
- yRibavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 92巻, 2号, pp. 210-218, 202002
- Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559巻, pp. 78-83, 20210625
- In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23巻, 1号, 202101
- Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40巻, 1号, 20210626
- Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21巻, 1号, 20210731
- Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28巻, 9号, pp. 1304-1311, 202109
- Infection courses, virological features and IFN-alpha responses of HBV genotypes in cell culture and animal models, JOURNAL OF HEPATOLOGY, 75巻, 6号, pp. 1335-1345, 202112
招待講演、口頭・ポスター発表等
- 日本消化器病学会総会, 2019年, 日本語
- American Association for the Study of Liver Diseases(AASLD2018), 通常, 英語, San Francisco
- American Association for the Study of Liver Diseases(AASLD2019), 2019年, 通常, 英語
受賞
- 2019年, 日本肝臓学会 研究奨励賞, 日本肝臓学会
- 2014年11月08日, Young Investigator Award, 日本内科学会
外部資金
競争的資金等の採択状況
- 科学研究費助成事業(若手研究), ヒト化肝炎マウスモデルの構築, 2021年, 2023年
- ウイルス肝炎研究財団研究助成事業(研究奨励金), ヒト肝細胞および免疫細胞を有するB型慢性肝炎モデルマウスの作成
- 土谷記念医学振興基金, B型肝炎ウイルス感染培養細胞およびモデルマウスを用いたcccDNAの制御および排除を目指した治療法の探索